Вміст брадикініну у крові хворих на COVID-19 та цукровий діабет

M.D. Tronko; V.V. Pushkarev; O.I. Kovzun; L.K. Sokolova; N.I. Levchuk; V.M. Pushkarev

doi:10.15407/dopovidi2024.04.072

Authors

M.D. Tronko V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0001-7421-0981
V.V. Pushkarev V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0001-5940-5510
O.I. Kovzun V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0002-6906-6636
L.K. Sokolova V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0003-0011-0106
N.I. Levchuk V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0003-0482-5176
V.M. Pushkarev V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0003-0347-7771

DOI:

https://doi.org/10.15407/dopovidi2024.04.072

Keywords:

coronavirus infection, bradykinin, diabetes

Abstract

Two hypotheses have been proposed to explain the causes of acute respiratory syndrome resulting from coronavirus-2 (SARS-CoV-2) infection: the cytokine storm theory and the bradykinin storm theory. From the first perspective, elevated levels of cytokines, primarily interleukin-6, cause the multisystem pathologic manifestations of COVID-19, including acute lung injury and respiratory distress syndrome in critically ill patients. The bradykinin storm theory emphasizes the importance of decreased levels of angiotensin-converting enzymes in lung epithelial cells, resulting in an inability to cleave bradykinin and the bradykinin analog des-Arg9-BK. The aim of the work was a comparative study of bradykinin levels in the blood of patients with diabetes mellitus and patients with mild and severe forms of COVID-19. It was shown that bradykinin levels were significantly increased in patients with diabetes mellitus. Patients with diabetes and COVID-19 showed a slight increase in bradykinin levels, which was not significantly different between diabetic patients and COVID-19 patients. In contrast, interleukin-6 was significantly increased in patients with diabetes and especially in patients with acute COVID-19.

Downloads

References

Tsymbalyuk, V. I., Tronko, M. D., Popova, V. V., Kovzun, O. I., Orlenko, V. L., Pushkarev, V. M., Sokolova, L. K.

& Pushkarev, V. V. (2023). COVID-19 and endocrine system. Bila Tserkva: Chas Zmin Inform (in Ukrainian).

Pushkarev, V. M., Kovzun, O. I., Levchuk, N. I., Pushkarev, V. V., Sokolova, L. K. & Tronko, M. D. (2023). The role of bradykinin in the development of COVID-19 and other diseases. Endokrynologia, 28, Nо. 4, pp. 349- 362 (in Ukrainian). https://doi.org/10.31793/1680-1466.2023.28-4.349

Turnic, T. N., Popadic, V., Klasnja, S., Sekulic, A., Nikolic, N., Zivkovic, V., Jeremic, N., Andjic, M., Draginic, N., Srejovic, I., Jeremic, J., Zdravkovic, M. & Jakovljevic, V. (2022). Bradykinin and galectin-3 in survived and deceased patients with COVID-19 pneumonia: an increasingly promising biochemical target. Oxid. Med. Cell. Longev., 2022, 7920915. https://doi.org/10.1155/2022/7920915

Wilczynski, S. A., Wenceslau, C. F., McCarthy, C. G. & Webb, R. C. (2021). A cytokine/bradykinin storm comparison: what is the relationship between hypertension and covid-19? Am. J. Hypertens., 34, Nо. 4, pp. 304-

https://doi.org/10.1093/ajh/hpaa217

Cooper, S. L., Boyle, E., Jefferson, S. R., Heslop, C. R. A., Mohan, P., Mohanraj, G. G. J., Sidow, H. A., Tan,

R. C. P., Hill, S. J. & Woolard J. (2021). Role of the renin-angiotensin-aldosterone and kinin-kallikrein systems in the cardiovascular complications of COVID-19 and long COVID. Int. J. Mol. Sci., 22, Nо. 15, 8255. https:// doi.org/10.3390/ijms22158255

Rex, D. A. B., Vaid, N., Deepak, K., Dagamajalu, S. & Prasad, T. S. K. (2022). A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases. Mol Biol Rep., 49, Nо. 10, pp. 9915- 9927. https://doi.org/10.1007/s11033-022-07539-2

Rex, D. A. B., Deepak, K., Vaid N., Dagamajalu S., Kandasamy R. K., Flo T. H. & Keshava Prasad, T. S. (2021). A modular map of bradykinin-mediated inflammatory signaling network. J. Cell Commun. Signal., 16, Nо. 2, pp. 301-310. https://doi.org/10.1007/s12079-021-00652-0

Hoevenaar, M., Goossens, D. & Roorda, J. (2020). Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. J. Renin Angiotensin Aldosterone Syst., 21, Nо. 4, 147032032097909. https://doi.org/10.1177/1470320320979097

Campbell, D. J. (2018). Neprilysin inhibitors and bradykinin. Front. Med. (Lausanne), 5, 257. https://doi. org/10.3389/fmed.2018.00257

Hirano, T. (2021). IL-6 in inflammation, autoimmunity and cancer. Int. Immunol., 33, Nо. 3, pp. 127-148. https://doi.org/10.1093/intimm/dxaa078

Sharma, J. N. (2014). Basic and clinical aspects of bradykinin receptor antagonists. Prog. Drug Res., 69, pp. 1-14. https://doi.org/10.1007/978-3-319-06683-7_1

Dagnino, A. P. A., Campos, M. M. & Silva, R. B. M. (2020). Kinins and their receptors in infectious diseases. Pharmaceuticals (Basel), 13, Nо. 9, 215. https://doi.org/10.3390/ph13090215

Lau, J., Rousseau, J., Kwon, D., Bénard, F. & Lin, K.-S. (2020). A systematic review of molecular imaging agents targeting bradykinin B1 and B2 receptors. Pharmaceuticals (Basel), 13, Nо. 8, 199. https://doi.org/10.3390/ ph13080199

BRADYKININ CONTENT IN THE BLOOD OF PATIENTS WITH COVID-19 AND DIABETES MELLITUS

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Most read articles by the same author(s)

Language

1

ISSN